Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. Published first on TheFly – the ultimate source for ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.58 which represents a decrease of $-2.15 or -2.13% from the prior close of $100.73. The stock opened at $100.76 and touched ...

These include the Coca-Cola Co. (KO) at $275 billion and Merck & Co. (MRK ... be found on the Chicago Board Options Exchange, New York Stock Exchange and Nasdaq. In early August 2024, ethereum prices ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...